Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

387
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
387
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

323
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
323
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovarian ependymoma presenting in pregnancy: a case report and literature review.

BMC pregnancy and childbirth·2020
Same author

Hydroxysafflor Yellow A Attenuates Hydrogen Peroxide-Induced Oxidative Damage on Human Umbilical Vein Endothelial Cells.

Evidence-based complementary and alternative medicine : eCAM·2020
Same author

2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside modulated human umbilical vein endothelial cells injury under oxidative stress.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology·2020
Same author

Evaluation of the impact of suspended particles on the UV absorbance at 254 nm (UV<sub>254</sub>) measurements using a submersible UV-Vis spectrophotometer.

Environmental science and pollution research international·2020
Same author

Ferulic acid (FA) protects human retinal pigment epithelial cells from H<sub>2</sub> O<sub>2</sub> -induced oxidative injuries.

Journal of cellular and molecular medicine·2020
Same author

SIRT1 Is the Target Gene for 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside Alleviating the HUVEC Senescence.

Frontiers in pharmacology·2020
Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026
Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026
Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026
Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026
Same journal

Dose-Dependent Escitalopram-Induced Anejaculation and Anorgasmia: Rapid Reversal After Discontinuation and Bupropion Therapy.

American journal of therapeutics·2026
Same journal

Critical Appraisal of "Continued versus Interrupted Oral Anticoagulation During Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: A Meta-Analysis".

American journal of therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Statistical Primer on Biosimilar Clinical Development.

Leah Isakov1, Bo Jin, Ira Allen Jacobs

  • 11Biotechnology Clinical Development Statistics, Pfizer Inc, Cambridge, MA; and 2Global Established Pharma Medicines Development Group, Pfizer Inc, New York, NY.

American Journal of Therapeutics
|January 15, 2016
PubMed
Summary
This summary is machine-generated.

Biosimilars are highly similar to originator biologics but not generic equivalents. Understanding statistical methods is key for clinicians to evaluate biosimilar similarity and make informed prescribing decisions.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.8K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K

Related Experiment Videos

Last Updated: Mar 27, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.8K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K

Area of Science:

  • Pharmacology
  • Biotechnology
  • Regulatory Science

Background:

  • Biosimilars are biological products highly similar to reference (originator) products, sharing no clinically meaningful differences in safety, purity, or potency.
  • Unlike small-molecule drugs, biosimilars are complex proteins and cannot be considered generic equivalents.
  • Regulatory approval processes for biosimilars differ significantly from those for generics due to their complex nature.

Purpose of the Study:

  • To review statistical concepts and terminology used in the clinical development of biosimilars.
  • To enhance clinician understanding of how biosimilar similarity is evaluated.
  • To support informed prescribing decisions regarding approved biosimilars.

Main Methods:

  • Review of statistical approaches and study designs specific to biosimilar clinical development.
  • Explanation of key concepts and terminology in biosimilar statistical analysis.
  • Focus on methods used to establish similarity between biosimilar and reference products.

Main Results:

  • Clinicians need to understand specialized statistical methods to assess biosimilarity.
  • The evaluation of biosimilars requires different study designs and statistical approaches compared to generics.
  • Understanding these statistical considerations is crucial for regulatory approval and clinical adoption.

Conclusions:

  • Statistical evaluation is central to demonstrating biosimilarity.
  • Educating clinicians on biosimilar statistical analysis facilitates appropriate use.
  • Informed prescribing decisions rely on a clear understanding of biosimilar clinical trial data and statistical rigor.